SystImmune to Unveil Groundbreaking Phase 3 Findings on Iza-bren at ESMO 2026
SystImmune, Inc., a biopharmaceutical company at the forefront of cancer therapies, has announced that four abstracts regarding its innovative drug, Iza-bren (izalontamab brengitecan), will be presented at the European Society for Medical Oncology (ESMO) Congress 2026. This prestigious event, scheduled for October 23-27 in Madrid, Spain, will showcase findings that highlight Iza-bren's potential across various cancer types, including EGFR-mutated non-small cell lung cancer (NSCLC) and HR+ breast cancer.
Iza-bren is a pioneering bispecific antibody-drug conjugate aimed at targeting cancer cells expressing both EGFR and HER3, markers that play essential roles in the progression of several epithelial cancers. The drug's dual-action mechanism not only induces cancer cell death through its unique payload but also inhibits the signaling pathways that promote cancer cell survival. This makes Iza-bren a promising candidate for patients with limited treatment options, particularly in cases of advanced cancer.
SystImmune's presentations will include:
1. Phase III Study in EGFR-mutant NSCLC: This late-breaking study focuses on the efficacy of Iza-bren compared to traditional platinum-based chemotherapy among Chinese patients whose NSCLC has progressed following third-generation EGFR tyrosine kinase inhibitors (TKIs). This research addresses critical gaps in treatment for a demographic often faced with fewer therapeutic avenues.
2. Phase III Study in HR+ Breast Cancer: Another significant study evaluates Iza-bren in patients with locally advanced or metastatic HR+/HER2- breast cancer who have previously undergone treatment with endocrine therapy and CDK4/6 inhibitors. This research seeks to provide new insights into treatment strategies for this resistant cancer type, known for its complex clinical challenges.
3. Combination Study with Pembrolizumab: A Phase II study exploring the combination of Iza-bren and pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma represents an exciting exploration of combining targeted therapy with immunotherapy, potentially enhancing treatment efficacy.
4. Combinatorial Strategy with Osimertinib: Another Phase II study is assessing Iza-bren in combination with osimertinib, an EGFR TKI, among treatment-naive patients suffering from EGFR-mutant locally advanced or metastatic NSCLC. This approach aims to investigate the effectiveness of dual-target strategies in achieving improved patient outcomes.
Dr. Jonathan Cheng, Chief Medical Officer of SystImmune, emphasizes that the data to be showcased at ESMO reflects the company's ongoing dedication not only to the development of Iza-bren but also to understanding its full therapeutic potential across various tumor types. "The presentations illustrate our commitment to advancing treatment options for patients facing the daunting challenges of difficult-to-treat cancers. We are excited to share these milestones with the medical community and look forward to their implications for oncology," he stated.
The upcoming presentations at ESMO 2026 are set to underscore the transformative potential of Iza-bren in the oncology landscape. As SystImmune continues to develop innovative cancer therapies, these findings could signify major advancements in the approach to treating aggressive forms of cancer. Attendees of the ESMO Congress can anticipate a wealth of information that may reshape future treatments and enhance patient care in oncology.
For more information regarding the abstracts and the ongoing development of Iza-bren, please refer to SystImmune’s official communications during the conference.
The Importance of Iza-bren
Iza-bren is a pioneering bispecific antibody-drug conjugate aimed at targeting cancer cells expressing both EGFR and HER3, markers that play essential roles in the progression of several epithelial cancers. The drug's dual-action mechanism not only induces cancer cell death through its unique payload but also inhibits the signaling pathways that promote cancer cell survival. This makes Iza-bren a promising candidate for patients with limited treatment options, particularly in cases of advanced cancer.
Key Presentations at ESMO 2026
SystImmune's presentations will include:
1. Phase III Study in EGFR-mutant NSCLC: This late-breaking study focuses on the efficacy of Iza-bren compared to traditional platinum-based chemotherapy among Chinese patients whose NSCLC has progressed following third-generation EGFR tyrosine kinase inhibitors (TKIs). This research addresses critical gaps in treatment for a demographic often faced with fewer therapeutic avenues.
2. Phase III Study in HR+ Breast Cancer: Another significant study evaluates Iza-bren in patients with locally advanced or metastatic HR+/HER2- breast cancer who have previously undergone treatment with endocrine therapy and CDK4/6 inhibitors. This research seeks to provide new insights into treatment strategies for this resistant cancer type, known for its complex clinical challenges.
3. Combination Study with Pembrolizumab: A Phase II study exploring the combination of Iza-bren and pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma represents an exciting exploration of combining targeted therapy with immunotherapy, potentially enhancing treatment efficacy.
4. Combinatorial Strategy with Osimertinib: Another Phase II study is assessing Iza-bren in combination with osimertinib, an EGFR TKI, among treatment-naive patients suffering from EGFR-mutant locally advanced or metastatic NSCLC. This approach aims to investigate the effectiveness of dual-target strategies in achieving improved patient outcomes.
Commitment to Patient Care
Dr. Jonathan Cheng, Chief Medical Officer of SystImmune, emphasizes that the data to be showcased at ESMO reflects the company's ongoing dedication not only to the development of Iza-bren but also to understanding its full therapeutic potential across various tumor types. "The presentations illustrate our commitment to advancing treatment options for patients facing the daunting challenges of difficult-to-treat cancers. We are excited to share these milestones with the medical community and look forward to their implications for oncology," he stated.
Conclusion
The upcoming presentations at ESMO 2026 are set to underscore the transformative potential of Iza-bren in the oncology landscape. As SystImmune continues to develop innovative cancer therapies, these findings could signify major advancements in the approach to treating aggressive forms of cancer. Attendees of the ESMO Congress can anticipate a wealth of information that may reshape future treatments and enhance patient care in oncology.
For more information regarding the abstracts and the ongoing development of Iza-bren, please refer to SystImmune’s official communications during the conference.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.